Tesamorelin vs CJC-1295: Comparing Two GHRH-Class Secretagogues
By Peptura Research Team/17 May 2026/7 min read
The Secretagogue Class
Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic peptide that prompts the anterior pituitary to release growth hormone (GH). Both Tesamorelin and CJC-1295 are synthetic GHRH analogues, but they part ways on molecular modification, pharmacokinetics, and pulsatility. Researchers working on the GH axis often weigh them against each other when a protocol turns on endogenous release patterns versus sustained elevation.
Tesamorelin: The Full-Length, Stabilised Analogue
Tesamorelin is a 44-amino-acid GHRH analogue carrying a trans-3-hexenoic acid moiety on its N-terminus. That addition shields the peptide from dipeptidyl peptidase-4 (DPP-4), which would otherwise cleave native GHRH within minutes. The upshot is a peptide that keeps the full native GHRH sequence and signalling profile while lasting far longer in vivo. Crucially, Tesamorelin preserves the natural pulsatile pattern of GH secretion, so research models show peaks and troughs in line with physiological rhythms.
CJC-1295: Truncated GHRH(1-29), With or Without DAC
CJC-1295 is a 30-amino-acid truncated GHRH(1-29) analogue with four amino acid substitutions that sharpen its resistance to enzymatic degradation and lift receptor binding affinity. It comes in two research forms: CJC-1295 without DAC, also known as Mod GRF 1-29, and CJC-1295 with DAC, where a maleimidopropionic acid linker (the Drug Affinity Complex) binds circulating albumin. Without DAC, its half-life sits near 30 minutes and pulsatile GH release survives. With DAC, the half-life stretches to about 8 days and elevation becomes sustained rather than pulsatile.
Pulsatile Versus Sustained
The pulsatile-versus-sustained distinction is mechanistically decisive. Native mammalian GH secretion is pulsatile, with peaks every 3 to 5 hours and troughs near zero. That pulsatility activates STAT5b-dependent gene expression in target tissues such as the liver, shaping IGF-1 production in characteristic patterns. Sustained elevation, as CJC-1295 with DAC produces, flattens the signalling curve and recruits different downstream transcriptional pathways. Tesamorelin and non-DAC CJC-1295 keep the pulse; DAC-modified CJC-1295 erases it. Which you choose usually comes down to whether physiological pulsatility is part of the question.
Research Applications
Tesamorelin has been studied extensively in HIV-associated lipodystrophy research, where visceral adipose tissue reduction was shown in clinical trials published by Falutz and colleagues in the New England Journal of Medicine in 2007. CJC-1295, with and without DAC, has served research on GH/IGF-1 axis kinetics, body-composition models, and combination protocols with GH-releasing peptide analogues such as Ipamorelin. Pairing a GHRH analogue with a ghrelin-mimetic GHRP is itself a frequently studied protocol in pituitary signalling research.
Laboratory Handling
Both peptides come as lyophilised powder. Store at -20°C before reconstitution. Reconstitute with bacteriostatic water by running it slowly down the side of the vial and swirling gently. Keep reconstituted solutions at 2-8°C and use within four weeks. Both Tesamorelin and CJC-1295 are sensitive to repeated freeze-thaw cycles that compromise integrity.
Sourcing in the UK
Peptura supplies research-grade Tesamorelin 5mg, CJC-1295 5mg, and CJC-1295 with DAC 5mg with full third-party Certificate of Analysis published on every product page. Same-day UK dispatch on orders before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.